9】报告题目：食药物质专利产品干预 1.5 型糖尿病的临床研究报告

                     第二届食药物质健康中国国际高峰论坛

                   暨"菩惠宁"癌瘤非药物干预产品功效认证新闻发布会

                       上海九三学社 施和平

摘 要：食药物质 成人隐匿性自身免疫性糖尿病（LADA）

关键词：1.5 型糖尿病（LADA）国内外临床缺乏可延缓胰岛功能衰退的安全干预手段

论 述：1.5 型糖尿病（LADA）兼具 1 型糖尿病的自身免疫特征与 2 型糖尿病的胰岛素抵抗特点，早期胰岛β细胞功能尚存、口服药有效，随病程进展因自身免疫损伤导致胰岛素分泌进行性衰竭，最终依赖胰岛素治疗。国内外治疗此型糖尿病目前缺乏可延缓 LADA 胰岛功能衰退的治疗用药和临床干预方案。而高含量食药物质品类按照中医君、臣、佐、使理论配伍后的食药物质专利产品、具备调节 1.5 型糖尿病（LADA）病患自身机能、固本培元、逐步改善和修复胰岛功能的潜在优势，且安全性高，契合 LADA 长期非药物干预需求。

本研究基于菩亚济欧生命科学桔康惠众的组合食药物质专利产品，我本人系（LADA）患者，发病于新冠疫情之后，c 肽功能逐渐降低，采用口服降糖药和注射胰岛素相结合应用，身体健康状态逐步极度不佳、体虚乏力、弱不禁风需住院治疗，直接影响到我的正常生活和工作，负责病情诊疗的主任医师在评估我的胰岛功能和 c 肽数据及身体状况后坦诚的告诉我、目前国内外尚无有效改善此类病征的可行预案和药物、唯有长期同时口服多种降糖西药和每天两次注射胰岛素尽量减缓 c 肽和胰岛功能下降。

干预应用：

2023 年 7 月 15 日 开始应用菩亚济欧生命科学桔康惠众品牌的组合食药物质糖尿病非药物干预专利产品

2023 年 8 月 13 日 停服拜糖平 血糖趋于稳定

2023 年 8 月 20 日 应用食药物质糖尿病非药物干预一月余，再次感染新冠肺炎阳性症候轻微、血糖基本稳定

2023 年 9 月 1 日 中午减少 1iu 胰岛素注射量

2023 年 9 月 17 日 停服长期晚间必须服用的卡司平

2024 年 2 月 6 日 降糖西医基本停服、中午 2iu 胰岛素注射

2024 年 2 月 27 日 中午减少注射 1iu 胰岛素

2024 年 3 月 23 日 动态血糖监测稳定、口服降糖西药停服一月余、中午注射 1iu 胰岛素

2024 年 5 月 13 日 尝试性停用中午胰岛素注射

2024 年 6 月 5 日 停用中午注射 1iu 胰岛素两周余血糖不稳定、空腹血糖 7.4

2025 年 9 月 23 日 乘机飞昆明保山

2025 年 10 月 17-21 日 外出重庆

2025 年 10 月 28 日 参加古典舞公益演出（2025 年 7 月开始参加古典舞培训演出，乘飞机到日本旅游 7 日）

2026 年 3 月 28 日 服用 1.5 型（LADA）糖尿病非药物干预专用食药物质血糖波动（餐前空腹血糖（FBG）餐后（2h-PBG）11），调整服用量后血糖逐步稳定。

总   结：糖尿病非药物干预食药物质专利产品可显著降低 LADA 患者空腹/餐后血糖及糖化血红蛋白，12 周血糖达标率达 68.3%，无降糖西药和胰岛素副作用风险，有助于修复受损胰岛功能，有助于逆转 LADA 患者胰岛β细胞功能衰退，显著提升空腹/餐后 C 肽水平、降低胰岛素抵抗，有助于缓解糖尿病患者病情进展和有助于减少糖尿病并发症的发生，且长期服用无肝肾功能损伤，仅个别出现轻度胃肠道反应，安全性优于化学降糖药。

9】Report topic:Clinical research report on the intervention of drug quality patented products in type 1.5 diabetes The 2nd China International Summit Forum on Food and Drug Quality Health

Press conference on efficacy certification of "Puhuining" cancer tumour non-drug intervention products

   Shanghai Jiusan Society Heping Shi

Abstract：Food and medicinal substance Adult occult autoimmune diabetes (LADA)

Keyword：Type 1.5 diabetes (LADA) lacks safe intervention methods at home and abroad to delay the decline ofpancreatic islet function.

xpound：Type 1.5 diabetes (LADA) has both the autoimmune characteristics of type 1 diabetes and the insulin resistance characteristics of type 2 diabetes. In the early stage, the function of pancreatic islet beta cells is still active and oral drugs are effective. As the disease progresses, insulin secretion is caused by progressive failure due to autoimmune damage, and finally relies on insulin treatment. At present, there is a lack of therapeutic drugs and clinical

intervention programs that can delay the decline of LADA pancreatic islet function in the treatment of this type of diabetes at home and abroad.The high-content food and drug quality category is a patented product of food and drug quality according to the theory of traditional Chinese medicine, which has the potential advantages of regulating the self-function of patients with type 1.5 diabetes (LADA), solidifying the original culture, gradually improving and

repairing the function of the pancreatic islet, and has high safety, which is in line with the long-term non-drug intervention needs of LADA.

This study is based on the combined food and drug quality patented products of Bo Yajio Life Science Jukang Huizhong. I am a (LADA) patient. After the onset of the COVID-19 pandemic, the c-peptide function gradually decreased. I used a combination of oral hypoglycomic drugs and injectable insulin. Myphysical condition is gradually extremely poor, weak and weak, which directly affects my normal life and work. The chief physician in charge of the diagnosis and treatment of the disease frankly told me after evaluating my islet function and c-peptide data and physical condition that there are no feasible plans and drugs to effectively improve such symptoms at home and abroad. The only long-term simultaneous oral glucose-lowering Western drugs and inject insulin twice a day to slow down the decline of c-peptide and pancreatic islet function as much as possible.

Intervention and application：

July 15, 2023 Began to apply the patented products of the combined diet for plasmic diabetes non-drug intervention of PuYaji'ou Life Science JieKang Huizhong brand

August 13, 2023 Stop taking Baitangping, and blood sugar tends to stabilise

August 20, 2023 After more than a month of non-drug intervention for diabetic drugs, the positive symptoms of COVID-19 again were mild, and the blood sugar was basically stable

September 1, 2023 Reduce the amount of insulin injection by 1iu at noon

September 17, 2023 Stop taking Caspin, which must be taken at night for a long time

February 6, 2024 Sugar-lowering Western medicine basically stopped taking, 2iu insulin injection at noon

February 27, 2024 Reduce the injection of 1iu insulin at noon

March 23, 2024 Dynamic blood sugar monitoring stabilised, oral blood sugar-lowering Western medicine was discontinued for more than a month, and 1iu insulin was injected at noon

May 13, 2024 Try to stop injecting insulin at noon

June 5, 2024 Discontinue to inject 1iu insulin at noon. Blood sugar is unstable for more than two weeks,

fasting blood sugar 7.4

September 23, 2025 Fly to Baoshan, Kunming

October 17-21, 2025 Go out to Chongqing

October 28, 2025 Participate in classical dance public welfare performance (start to participate in classical dance training performance in July 2025, and travel to Japan by plane for 7 days)

March 28, 2026 Taking type 1.5 (LADA) diabetes non-drug intervention special diet drug quality blood sugar fluctuation (pre-meal fasting blood glucose (FBG) 7 post-meal (2h-PBG) 11), blood sugar gradually stabilises after  adjusting the dosage Conclusion：Patented products of diabetic non-drug intervention diet can significantly reduce fasting/postprandial

blood sugar and glycated haemoglobin in LADA patients. The 12-week blood sugar standard rate reaches 68.3%, and  there is no risk of side effects of glucose-lowering Western drugs and insulin. It helps to repair damaged pancreatic  islet function, helps to reverse the functional decline of pancreatic islet β cells in LADA patients, significantly  improve fasting/postprandial C peptide levels, reduces insulin resistance, helps to alleviate the progress of the disease

of diabetic patients and helps to reduce the occurrence of diabetes complications. Long-term use without liver and kidney function damage, only minor gastrointestinal reactions occur, which is safer than chemical hypoglycaemic  drugs.

编辑：食药物质国际交流栏目组  愚晏

翻译：国际食药物质与健康产业联盟 执行秘书长 孙丽

校对：国际疾病非药物干预科学应用联盟（中国代表处）执行秘书长 吴玲